Core Viewpoint - Haizheng Pharmaceutical (600267) announced that its subsidiary, Zhejiang Haizheng Animal Health Products Co., Ltd., has received approval from the Ministry of Agriculture and Rural Affairs of the People's Republic of China for the new veterinary drug registration certificate for Nirocoxib Chewable Tablets, officially classified as a Class II new veterinary drug [1] Group 1 - The new veterinary drug, Nirocoxib Chewable Tablets, is intended for alleviating pain and inflammation caused by canine osteoarthritis and clinical surgeries [1] - The registration application for Nirocoxib Chewable Tablets was submitted in June 2022, and it was processed by the Ministry of Agriculture and Rural Affairs along with other entities [1] - The product is now ready for production and will be launched once it obtains the veterinary product approval number, but it is not expected to have a significant impact on the company's performance in the short term [1]

Group 1 - The company has approved a plan to repurchase its shares through centralized bidding, with a total fund of no less than RMB 50 million and no more than RMB 100 million, at a price not exceeding RMB 13 per share, within a 12-month period [1] - As of May 22, 2025, the company has repurchased 582,000 shares, accounting for 0.05% of the total share capital, with a total expenditure of RMB 5,317,259, and the highest and lowest purchase prices being RMB 9.18 and RMB 9.08 per share respectively [2] - By the end of May 2025, the cumulative repurchased shares reached 1,347,000, representing 0.11% of the total share capital, with a total expenditure of RMB 12,249,660, and the highest and lowest purchase prices being RMB 9.22 and RMB 8.92 per share respectively [2] Group 2 - The company will strictly adhere to relevant regulations during the repurchase period and will make repurchase decisions based on market conditions, ensuring timely information disclosure regarding the progress of the repurchase [4]

本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 证券代码：600267 证券简称：海正药业 公告编号：临 2025-33 号 浙江海正药业股份有限公司 关于第四次以集中竞价交易方式回购公司股份的进展 公告 截至 2025 年 5 月月底，公司已累计回购股份 1,347,000 股，占公司总股本的 比例为 0.11%，购买的最高价为 9.22 元/股、最低价为 8.92 元/股，已支付的总金额 为 12,249,660.00 元（不含交易费用）。 重要内容提示： | 回购方案首次披露日 | 2025/5/13 | | | | | | | --- | --- | --- | --- | --- | --- | --- | | 回购方案实施期限 | 2025 年 5 月 5 | 12 | 日~2026 | 年 | 月 | 11 日 | | 预计回购金额 | 5,000万元~10,000万元 | | | | | | | 回购用途 | □减少注册资本 √用于员工持股计划或股权激励 | | | | | | | | □用于转换公司可转债 | ...

Core Viewpoint - The core strategy of Haizheng Pharmaceutical is to return to the top tier of the domestic market by focusing on human medicine while developing animal medicine and health products as complementary wings [1] Group 1: Business Strategy and Development - Haizheng Pharmaceutical aims to establish a diversified development pattern with a focus on human medicine and two wings: animal medicine and health products [1] - The company has transformed its original raw material plant into a biopharmaceutical industrial park covering over 1,500 acres, encompassing high-end biopharmaceuticals, injectable and oral formulations, and export raw materials [1][3] - The company has been exporting raw materials to over 70 countries and regions since 1992, with more than 400 overseas clients, including major global pharmaceutical companies [3] Group 2: Production and Quality Control - Haizheng Pharmaceutical emphasizes the importance of high-quality raw materials, with production bases in Taizhou, Fuyang, and Nantong, featuring a complete production line with fermentation capacity of 17,000 cubic meters and synthesis capacity of 2,300 cubic meters [6] - The Fuyang base has established an international standard QEHS system and has successfully undertaken CMO orders from international giants like Merck and Codexis [6][12] - The company has passed inspections from various global regulatory bodies, including WHO, FDA, and EMA, demonstrating its commitment to quality [12] Group 3: Innovation and Product Development - The company has accelerated its transition from raw materials to formulation business, with its subsidiary Hanhui Pharmaceutical achieving significant sales growth [8][10] - Haizheng Pharmaceutical has developed its first-class innovative drug, Haibomab, which has enriched its product line [10] - The company has successfully completed technology transfers for several original products, filling gaps in domestic technology transfer for original products [10] Group 4: Animal Health Sector - The animal health sector is a key focus for Haizheng Pharmaceutical, leveraging its expertise in human medicine standards to create high-quality veterinary products [14] - The company has established a comprehensive product matrix covering pets, pigs, and ruminants, with a commitment to rigorous quality standards [15] - Haizheng Animal Health has achieved significant milestones, including the first domestic deworming drug with sales exceeding 100 million and successful market entries in countries like Vietnam [15]

Group 1 - The Artemisinin concept sector rose by 1.17%, ranking 7th among concept sectors, with six stocks increasing in value, including Fosun Pharma, Zhejiang Medicine, and Haizheng Pharmaceutical, which rose by 5.23%, 4.94%, and 1.54% respectively [1] - The leading stocks in terms of net inflow of main funds were Zhejiang Medicine, Fosun Pharma, Baiyun Mountain, and Haizheng Pharmaceutical, with net inflows of 856.29 million, 545.22 million, 103.85 million, and 52.54 million respectively [1] - The main fund inflow rates for Zhejiang Medicine, Baiyun Mountain, and Fosun Pharma were 7.58%, 7.56%, and 3.62% respectively [2] Group 2 - The top gainers in the concept sector included pork, chicken farming, innovative drugs, and animal vaccines, while the top losers included controllable nuclear fusion and decelerators [1] - The overall market performance showed a mixed trend, with some sectors experiencing significant gains while others faced declines [1] - The trading volume and turnover rates varied among the stocks, indicating differing levels of investor interest and activity [2][3]

Group 1 - The animal vaccine sector increased by 1.35%, ranking fourth among concept sectors, with 13 stocks rising, including Kexing Pharmaceutical, Kanghua Biological, and Dongfang Biological, which rose by 7.40%, 6.06%, and 5.85% respectively [1][2] - The leading stocks in terms of net inflow of main funds include Tiankang Biological with a net inflow of 17.69 million, followed by Dongfang Biological, Dabeinong, and Haizheng Pharmaceutical with net inflows of 17.19 million, 7.87 million, and 5.25 million respectively [2][3] - The main fund inflow rates for Dongfang Biological, Haili Biological, and *ST Xianfeng are 9.15%, 6.15%, and 5.51% respectively [3] Group 2 - The top gainers in the animal vaccine sector include Kexing Pharmaceutical with a rise of 7.40% and Kanghua Biological with a rise of 6.06%, while the biggest losers include Weilan Biological, Jinhai Biological, and Plai Ke, which fell by 1.82%, 1.26%, and 1.08% respectively [1][4] - The overall net outflow of main funds from the animal vaccine sector was 4.75 million, indicating a mixed sentiment among investors [2]

Summary of Key Points Core Viewpoint - Zhejiang Haizheng Pharmaceutical Co., Ltd. has announced its fourth share repurchase plan, aiming to enhance shareholder value and support employee stock ownership plans, with a total repurchase amount expected between 50 million and 100 million RMB [1][2]. Group 1: Share Repurchase Plan - The repurchase plan was first disclosed on May 13, 2025, and will be implemented from May 12, 2025, to May 11, 2026 [1]. - The total amount allocated for the repurchase is between 50 million RMB and 100 million RMB, with a maximum purchase price set at 13 RMB per share [1][2]. - The company has already repurchased 582,000 shares, which accounts for 0.05% of the total share capital, with a total expenditure of 5,317,259 RMB [1][2]. Group 2: Progress of Share Repurchase - The repurchase has been conducted in accordance with the established plan, with the highest purchase price recorded at 9.18 RMB per share and the lowest at 9.08 RMB per share [2]. - The total amount paid for the repurchased shares, excluding transaction fees, is 5,317,259 RMB [2]. - The company will continue to make repurchase decisions based on market conditions and will fulfill its information disclosure obligations regarding the progress of the repurchase [2].

本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： | 回购方案首次披露日 | 2025/5/13 | | --- | --- | | 回购方案实施期限 | 2025/5/12~2026/5/11 | | 预计回购金额 | 5,000万元~10,000万元 | | 回购用途 | □减少注册资本 √用于员工持股计划或股权激励 | | | □用于转换公司可转债 | | | □为维护公司价值及股东权益 | | 累计已回购股数 | 582,000股 | | 累计已回购股数占总股本比例 | 0.05% | | 累计已回购金额 | 5,317,259.00元 | | 实际回购价格区间 | 9.08元/股~9.18元/股 | 一、 回购股份的基本情况 证券代码：600267 证券简称：海正药业 公告编号：临 2025-32 号 浙江海正药业股份有限公司 关于第四次以集中竞价交易方式回购公司股份方案 首次实施回购的公告 特此公告。 浙江海正药业股份有限公司董事会 2025 年 5 月 22 日，公司通过集中竞价交易方式首次回购股份 ...

Core Viewpoint - Haizheng Pharmaceutical (600267) aims to adopt a differentiated strategy focusing on solidifying its industrial foundation, with emphasis on synthetic biology and high-end manufacturing [1] Group 1: Company Overview - Established in 1956, Haizheng Pharmaceutical started with raw materials and has evolved into a comprehensive pharmaceutical enterprise covering the entire value chain from research and production to sales [1] - The company operates a significant production base in Fuyang, Zhejiang, which spans over 1,500 acres and includes various subsidiaries [1] Group 2: Raw Material Business - The raw material segment is a traditional focus for Haizheng, leveraging technological and production scale advantages [2] - The company has developed over a hundred raw material drug varieties, utilizing a fermentation semi-synthesis technology platform [2] - Haizheng is expanding into the health sector, particularly in medical aesthetics and industrial raw materials, to enhance its sales capabilities [2] Group 3: Production Capabilities - Haizheng has established three major production bases in Taizhou, Fuyang, and Nantong, with a complete production line layout [2] - The Fuyang base features 17 independent production lines and adheres to a production philosophy of "pipeline, closed, continuous, and automated" [2] - The base has successfully secured CMO orders from international giants like Merck and continues to advance new product registrations [2] Group 4: Pharmaceutical Formulation Business - Haizheng has achieved a leading position in exporting injectable drugs to the U.S. market, maintaining high GMP standards [3] - The formulation business is primarily managed by its subsidiary, Hanhui Pharmaceutical, which has developed a unique quality management model [3] - Hanhui has successfully completed technology transfers for several original research products, addressing domestic supply shortages [3] Group 5: Animal Health Sector - The animal health segment is a key area of focus, with Haizheng leveraging its bases to create a diverse product matrix for livestock and pets [3] - Haizheng Animal Health has obtained multiple certifications and has several products with significant sales, including a record-breaking domestic deworming drug [3] - The company has a production capacity of 3,000 acres, allowing for strategic positioning in human and animal pharmaceuticals, both domestically and internationally [3]

Core Viewpoint - The animal vaccine sector has shown a significant increase, with a 4.00% rise, ranking third among concept sectors, driven by notable gains in several stocks [1][2]. Group 1: Sector Performance - As of May 20, the animal vaccine concept increased by 4.00%, with 19 stocks rising, including *ST Xianfeng, which hit the daily limit, and others like Kexing Pharmaceutical, Ruipu Biological, and Kanghua Biological, which rose by 15.56%, 8.41%, and 6.70% respectively [1][2]. - The animal vaccine sector was among the top-performing sectors, alongside cultivated diamonds and pet economy, which rose by 4.10% and 4.08% respectively [2]. Group 2: Capital Inflow - The animal vaccine sector saw a net inflow of 67 million yuan, with 13 stocks receiving net inflows, and 6 stocks attracting over 10 million yuan in net inflows [2]. - Jinhe Biological led the net inflow with 36.88 million yuan, followed by Kexing Pharmaceutical, Dabeinong, and Plk, which received net inflows of 15.38 million yuan, 13.79 million yuan, and 13.60 million yuan respectively [2][3]. Group 3: Capital Flow Ratios - Stocks such as *ST Xianfeng, Kexing Pharmaceutical, and KQ Biotech had the highest net inflow ratios, at 14.17%, 6.56%, and 5.52% respectively [3]. - The top stocks in terms of capital inflow included Jinhe Biological with a turnover rate of 18.22% and a daily increase of 4.40%, and Kexing Pharmaceutical with a turnover rate of 3.46% and a daily increase of 15.56% [3][4].